Abstract
Novel nitrogen-containing heterocyclic compounds were claimed as inhibitors of p38 mitogen-activating protein kinase (MAPK), which can be useful for the treatment of a variety of inflammatory, autoimmune, bone-related, proliferative, infectious, angiogenic and neurodegenerative diseases.